



Retrospective Safety Review Solution Fact Sheet

This program acts as a safety net for serious drug interactions that may have a negative clinical impact on a member and that were not addressed at the point of sale. Retail and mail service prescriptions are reviewed daily. When an edit is triggered, a clinical pharmacist evaluates the opportunity for intervention within 72 hours for drug-drug interaction targets. If the opportunity warrants intervention, the clinical pharmacist will send a letter to the prescribing physician, indicating the drug-drug interaction along with a complete copy of the member's medication profile. In some cases, when the drug interaction will have an immediate onset, the clinical pharmacist will contact the pharmacy and/or patient by phone.

The near real-time retrospective intervention may allow for a change in the prescription before the member picks up the original prescription, resulting in increased member safety, less member disruption and earlier savings capture.

Edit Criteria	<p>Edits identify and intervene on specific serious drug-drug interaction claims.</p> <p>Edits include:</p> <ul style="list-style-type: none"> • Serious drug-drug interactions that are overridden at point-of-service, but warrant review will be reviewed through this solution 			
Target Drugs*	Allopurinol Amiodarone Antifungals Antiretrovirals Bosentan Capecitabine Carbamazepine Clonidine Cyclosporine Digoxin Ergot Alkaloids	Fenofibrate Lithium Loop Diuretics MAOIs Methotrexate PDE5 Inhibitors Penicillins Pimozide K-Sparring Diuretics Propafenone	Protease Inhibitors Quinidine Quinolones Ramelteon Ranolazine Rifamycins Ritonavir & Nelfinavir Ritonavir Selected CCBs	Selected Statins Simvastatin SRIs Statins TCAs Theophylline Thoridazine Triptans Warfarin
Process Flow	<p>System Review The system identifies and flags all claims for target drugs filled for a member whose profile also includes claims for drugs that could pose a safety issue when combined with the target drugs (i.e., warfarin and statins).</p> <p>Clinical Review Clinical pharmacist reviews flagged claims to identify and intervene on the most severe drug-to-drug interactions within 72 hours of adjudication.</p> <p>Intervention A letter with the patient profile is sent to the prescriber on all appropriate interventions.</p>			

*Target drugs are constantly reviewed and updated. This list is subject to change.

To learn more about how this solution can work for your plan, please contact your CVS Caremark Account Representative.